9,733 DexCom, Inc. $DXCM Shares Sold by Howard Capital Management LLC

Howard Capital Management LLC decreased its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 79.6% in the 3rd quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 2,488 shares of the medical device company’s stock after selling 9,733 shares during the quarter. Howard Capital Management LLC’s holdings in DexCom were worth $215,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds also recently modified their holdings of DXCM. Reflection Asset Management acquired a new position in shares of DexCom during the 4th quarter valued at $25,000. Ascentis Independent Advisors bought a new position in DexCom during the first quarter worth $25,000. Wellington Grp LLC boosted its stake in DexCom by 778.7% during the first quarter. Wellington Grp LLC now owns 536 shares of the medical device company’s stock worth $34,000 after acquiring an additional 475 shares in the last quarter. Elevation Wealth Partners LLC grew its holdings in DexCom by 61.0% in the third quarter. Elevation Wealth Partners LLC now owns 401 shares of the medical device company’s stock worth $35,000 after purchasing an additional 152 shares during the period. Finally, GK Wealth Management LLC acquired a new stake in DexCom in the third quarter worth $35,000. Institutional investors own 97.75% of the company’s stock.

Insider Activity at DexCom

In related news, EVP Sadie Stern sold 2,565 shares of the company’s stock in a transaction on Monday, September 28th. The stock was sold at an average price of $86.15, for a total transaction of $220,974.75. Following the completion of the sale, the executive vice president owned 123,478 shares in the company, valued at approximately $10,637,629.70. This represents a 2.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Nicholas Augustinos sold 6,539 shares of the company’s stock in a transaction on Tuesday, September 15th. The stock was sold at an average price of $84.04, for a total value of $549,537.56. Following the sale, the director owned 29,293 shares of the company’s stock, valued at $2,461,783.72. This trade represents a 18.25% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 49,313 shares of company stock valued at $3,945,875 over the last 90 days. Corporate insiders own 0.28% of the company’s stock.

DexCom Price Performance

DXCM stock opened at $86.04 on Friday. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.43 and a current ratio of 1.73. The business has a 50-day simple moving average of $87.61 and a two-hundred day simple moving average of $75.86. The company has a market capitalization of $32.47 billion, a P/E ratio of 34.01, a price-to-earnings-growth ratio of 1.44 and a beta of 1.48. DexCom, Inc. has a 52-week low of $54.11 and a 52-week high of $92.59.

DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Thursday, July 30th. The medical device company reported $0.70 EPS for the quarter, topping the consensus estimate of $0.61 by $0.09. DexCom had a return on equity of 35.94% and a net margin of 20.12%. The firm had revenue of $1.31 billion during the quarter, compared to the consensus estimate of $1.29 billion. During the same period in the prior year, the business posted $0.48 earnings per share. The company’s quarterly revenue was up 13.1% compared to the same quarter last year. Research analysts expect that DexCom, Inc. will post 2.64 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several equities research analysts have weighed in on the stock. Canaccord Genuity Group set a $90.00 price target on shares of DexCom and gave the company a “buy” rating in a research note on Monday, August 3rd. Raymond James Financial reiterated a “strong-buy” rating and set a $94.00 price objective on shares of DexCom in a report on Friday, July 31st. Deutsche Bank Aktiengesellschaft began coverage on shares of DexCom in a research report on Tuesday, June 23rd. They set a “buy” rating and a $86.00 price objective on the stock. Wells Fargo & Company raised their target price on DexCom from $85.00 to $90.00 and gave the company an “overweight” rating in a research note on Friday, July 31st. Finally, Barclays upgraded DexCom to a “strong-buy” rating in a research note on Wednesday, October 7th. Three research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have assigned a Hold rating to the company. According to data from MarketBeat, the company has an average rating of “Buy” and an average target price of $92.43.

DexCom Profile

DexCom, Inc (NASDAQ: DXCM) develops and commercializes continuous glucose monitoring (CGM) systems for people with diabetes. Its technology uses a small wearable sensor to measure glucose levels continuously and transmit readings to a compatible receiver, smartphone or other connected device, helping users monitor glucose trends and make more informed treatment and lifestyle decisions.

The company’s product portfolio includes the Dexcom G7 and Dexcom G6 real-time CGM systems, as well as related software and digital health tools such as Dexcom Clarity for glucose data analysis and reporting.